Accéder au contenu
Merck

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2013-04-02)
M Gopal, N Padayatchi, J Z Metcalfe, M R O'Donnell
RÉSUMÉ

The increased incidence of drug-resistant tuberculosis has created an urgent necessity for the development of new and effective anti-tuberculosis drugs and for alternative therapeutic regimens. Clofazimine (CFZ) is a fat-soluble riminophenazine dye used in the treatment of leprosy worldwide. CFZ has also been used as a Group 5 drug in the treatment of tuberculosis (TB). A large cohort study from Bangladesh published in 2010 described a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) including CFZ as being highly effective against MDR-TB. We searched multiple databases for studies published through February 2012 that reported use of CFZ in MDR- and extensively drug-resistant TB (XDR-TB) treatment regimens. We identified nine observational studies (6 MDR-TB and 3 XDR-TB) including patients with drug-resistant TB treated with CFZ. Overall, 65% (95% confidence interval [95%CI] 54-76) of the patients experienced favorable outcomes, defined as either cure or treatment completion. Using random effects meta-analysis, 65% (95%CI 52-79) of those with MDR-TB and 66% (95%CI 42-89) of those with XDR-TB experienced favorable treatment outcomes. High-quality prospective cohort studies and clinical trials examining the effect of CFZ as part of drug-resistant TB treatment regimens are needed.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Clofazimine
Référence
Conditionnement
Disponibilité
Prix
Quantité
Clofazimine, European Pharmacopoeia (EP) Reference Standard
Référence
Conditionnement
Disponibilité
Prix
Quantité
Clofazimine for system suitability, European Pharmacopoeia (EP) Reference Standard
Référence
Conditionnement
Disponibilité
Prix
Quantité